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Abstract
Aim Propofol sedation is often associated with deep
sedation and decreased manoeuvrability. Patient-main-
tained sedation has been used in such patients with
minimal side-effects. We aimed to compare novel mod-
ified patient-maintained target-controlled infusion (TCI)
of propofol with patient-controlled Entonox inhalation
for colonoscopy in terms of analgesic efficacy (primary
outcome), depth of sedation, manoeuvrability and patient
and endoscopist satisfaction (secondary outcomes).
Method One hundred patients undergoing elective col-
onoscopy were randomized to receive either TCI propofol
or Entonox. Patients in the propofol group were admin-
istered propofol initially to achieve a target concentration
of 1.2 lg ⁄ml and then allowed to self-administer a bolus
of propofol (200 lg ⁄ kg ⁄ml) using a patient-controlled
analgesia pump with a handset. Entonox group patients
inhaled the gas through a mouthpiece until caecum was
reached and then as required. Sedation was initially given
by an anaesthetist to achieve a score of 4 (Modified
Observer’s Assessment of Alertness and Sedation Scale),
and colonoscopy was then started. Patients completed an
anxiety score (Hospital Anxiety and Depression question-
naire), a baseline letter cancellation test and a pain score
on a 100-mm visual analogue scale before and after the
procedure. All patients completed a satisfaction survey at
discharge and 24 h postprocedure.
Results The median dose of propofol was 174 mg, and
the median number of propofol boluses was four. There
was no difference between the two groups in terms of
pain recorded (95% confidence interval of the difference
)0.809, 5.02) and patient ⁄ endoscopist satisfaction.
There was no difference between the two groups in
either depth of sedation or manoeuvrability.
Conclusion Both Entonox and the modified TCI prop-
ofol provide equally effective sedation and pain relief,
simultaneously allowing patients to be easily manoeuvred
during the procedures.
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Introduction
Colonoscopy is generally performed with the patient
sedated using a combination of benzodiazepines and an
opioid [1–5], mostly midazolam and fentanyl or pethi-
dine (meperidine), which is the standard practice in many
countries. This kind of intravenous sedation is associated
with cardiorespiratory complications in up to 20% of
patients [6], delayed recovery of psychomotor function
and delayed discharge. The oxygen desaturation associ-
ated with these complications seems in part to be caused
by medication, even when titration of the dose is
attempted [3,7–9].
Therefore, an agent with a shorter duration of action
would be desirable; one that permitsmore rapid recovery of
function, while providing comparative patient comfort
during theprocedure and thathas a safetyprofile better than
the medications currently in use. Two such candidates we
studied are Entonox (nitrous oxide in air) and propofol.
We have previously shown that patient-controlled En-
tonox analgesia is superior to routine intravenous sedation
(midazolamand fentanyl) for colonoscopy [10].Entonox is
a weak inhalation anaesthetic agent with anaesthetic,
sedative and anxiolytic properties. At 50% concentrations,
it is an effective analgesic agent without respiratory
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depressant effects. It has a low blood ⁄ gas solubility ratio
and hence allows fast onset and clearance time.
Propofol is a sedative agent that has been shown to be
superior to benzodiazepines and narcotics with regard to
rapid induction of sedation [11], faster recovery [12,13]
and equivalent levels of amnesia [14,15]. Among gast-
roenterologists, there is increasing interest in the use of
propofol for endoscopic sedation, and the number of
reports of endoscopist-administered propofol efficacy is
growing [16–22]. However, propofol has a narrow
therapeutic index and can produce deep sedation, result-
ing in respiratory depression and even apnoea. As the
depth of sedation is a continuum, the doses required for
conscious sedation as used in colonoscopy are markedly
lower than those used for induction of anaesthesia [23].
Moreover, deeper sedation makes it difficult to manoeu-
vre a patient during colonoscopy. Thus, the two prob-
lems with propofol sedation are greater depths of
sedation and difficulty in manoeuvring the patients.
Target-controlled infusion (TCI) of propofol enables an
exact amount of the drug to be delivered, maintaining a
preset concentration of propofol in the blood or brain. This
technique, routinely used in anaesthetic practice, has
previously been used in colonoscopy, and Campbell et al.
[24] modified a TCI pump to achieve patient-maintained
sedation. However, this modification is not available from
the manufacturers and is only experimental, and its efficacy
has not been proved in large studies.Wedeveloped a target-
controlled patient-maintained (TCI-PCA) propofol seda-
tion protocol in our unit. In this protocol, propofol
sedation was initiated with a TCI pump to achieve a preset
effect-site concentration, and subsequently sedation was
maintainedby the patientsusing a simplepatient-controlled
analgesia pump (PCA) delivering propofol on demand.
Moreover, though there have been studies [23,25,26]
comparing propofol with routine intravenous sedation,
there is no comparison between PCA-TCI propofol and
Entonox.
Based on this background, we performed the study
with the aim of primarily comparing TCI-PCA propofol
with Entonox in terms of analgesic efficacy (primary
outcome), and also depth of sedation, manoeuvrability,
rate of complications, recovery of psychomotor function
and time to discharge. We also aimed to establish the
safety and feasibility of using patient-maintained target-
controlled propofol as sedation for colonoscopy.
Method
Study design
This is a randomized controlled trial comparing Entonox
with TCI-PCA propofol for colonoscopy and was
performed in the endoscopy unit at Castle Hill Hospital,
Cottingham, UK from January 2005 to June 2006. This
is a tertiary hospital, and is one of the national endoscopy
training centres in the UK.
The studywas approvedby the SouthHumberResearch
Ethics Committee, UK and the Clinical Trials Unit,
Medicines and Health Regulatory Authority, London,
UK and registered with the European Clinical Trials
Database. The study was preregistered with the Inter-
national Standardised Randomised Controlled Trials
Database (available at http://www.controlled-trials.com/
isrctn; trial registration number ISRCTN65879800).
It was undertaken according to International Confer-
ence on Harmonisation good clinical practice standards,
including independent on-site monitoring and source
data verification.
Inclusion and exclusion criteria
All patients undergoing elective colonoscopy, including
males and females, were invited to participate in the trial
by sending letters and patient information leaflets
(approved by Ethics Committee) 2 weeks before the
intended procedure. Patients were given both oral and
written information regarding the trial and the drugs
involved once again when they reported for their colo-
noscopy. Subsequently, informed written consent was
obtained from all patients 15 min before they were
randomized to either group. The exclusion criteria are
shown in Table 1.
Randomization and allocation concealment
The participants were randomized by using block ran-
domization, with a block size of five used to make less
predictable what might be the next treatment allocation.
The assignments were held centrally in sequentially
numbered, opaque, sealed envelopes, and the envelopes
were opened sequentially and only after the participant’s
name, address, date of birth and other details were
written on the appropriate envelope. The randomization
sequence was generated by a person not involved in this
study, and he opened the envelope for allocation after a
telephone call.
None of the endoscopists was aware of the location of
these envelopes. Neither the patients nor the colonosco-
pists were blinded to the treatment modality after the
allocation.
Interventions
After informed written consent was obtained, patients
were randomly assigned to one of the two treatment
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groups: (1) propofol group or (2) inhaled Entonox
(BOC gases; UK) group.
Those patients who refused to participate were asked
about the reasons for doing so, including past experiences
with any of the drugs, whether they were frightened by
the idea of deciding their own sedation or any other
reason. All such patients completed pre- and postproce-
dure questionnaires, similar to the participants.
All participants completed a Hospital Anxiety and
Depression questionnaire and a baseline letter cancella-
tion test and marked their pain on a 100-mm visual
analogue scale (VAS) before randomization, but after
giving consent for the trial (Table 2).
Protocol for propofol
Patients randomized to the propofol group were
informed about the procedure and the reasons for
sedation as well the technique. Subsequently, propofol
was administered through an intravenous cannula using
our modified target-controlled infusion system. The
system consisted of a Graseby (Watford, Herts, UK)
3400 infusion pump, controlled by a microprocessor
system. The microprocessor in this pump is prepro-
grammed with the pharmacokinetic data describing the
distribution and elimination of propofol. The anaesthe-
tist entered the patient’s age and weight into the
microprocessor, and the system displayed the target
blood concentration and calculated effect-site (brain)
concentration. In addition, the anaesthetist was able to
manually override the system to alter the concentration
in the event of over-sedation.
Patients were given propofol through the pump to
achieve a target concentration of 1.2 lg ⁄ml ⁄ h. How-
ever, colonoscopy was started as soon as the depth of
sedation [as scored by the Modified Observer’s Assess-
ment of Alertness and Sedation Scale (MOAAS)] reached
a score of 4. Subsequently, patients were connected via a
Y-connector to another PCA (PCA-Graseby) pump
containing propofol, and were also given a handset.
Pressing the handset delivered a bolus of 200 lg ⁄ kg ⁄ml,
with a lockout period of 2 min. They were encouraged to
press the button during the procedure if they wanted to
feel sleepier. The anaesthetist was allowed to give
intravenous fentanyl if patients had pain or were uncom-
fortable during the procedure.
Protocol for Entonox
Patients randomized to Entonox were first told what the
gas was for and what was required of them. Entonox
Table 1 Monitoring of patients, discharge criteria, sedation
scoring and exclusion criteria.
Monitoring
1. 2–3 l oxygen given to all patients
2. Intravenous cannulae in situ before procedure in all
patients
3. Pulse oximetry
4. Clinical monitoring, including heart rate and blood
pressure. This is continued into the recovery area, and it
is the responsibility of both the endoscopists as well as the
nurse to monitor these physiological variables
5. Chest excursion and respiratory effort monitored by the
recovery nurse
6. Full resuscitation equipment available within easy reach in
endoscopy suite
Discharge criteria
1. Patient responds appropriately to questions and is able to
communicate clearly
2. Patient is able to sit upright for at least 5 min and is able to
tolerate liquids ⁄ solids
3. Patient is able to dress independently and use the toilet
Sedation scoring (ASA ⁄MOAAS)
5 responds readily to name spoken in normal tone
4 lethargic response to name spoken in normal tone
3 responds only after name is called loudly and ⁄ or repeatedly
2 responds only after mild prodding or shaking
1 responds only after painful trapezius squeeze
0 no response after painful trapezius squeeze
Exclusion criteria
1. Patients with chronic pulmonary disease
2. History of colonic resection
3. Intolerance to any of the drugs
4. Unwilling to enter the trial
5. ASA class IV
6. Allergy to soybeans, eggs
7. History of seizure disorder, sleep apnoea or difficult
intubation, a short thick neck and inability to open mouth
widely
Degree of manoeuvrability (manoeuvrability scoring)
1. Patient was awake and responded to all verbal commands
2. Drowsy and responded to most of the commands to move
(>50%)
3. Patient was able to move to some commands (<50%)
4. Quite difficult to manoeuvre and ⁄ or no response to verbal
commands to move (<10%)
Table 2 Administration of questionnaires to participants.
A. Precolonoscopy (after consent and before randomization)
1. Hospital Anxiety and Depression Scale
2. Letter cancellation test
3. 100 mm visual analogue scale
B. Postcolonoscopy
1. Visual analogue scale – immediately after procedure and at
15-min intervals up to and including at discharge; repeated
at 24 h postcolonoscopy
2. Letter cancellation test – immediately after procedure and
at 15-min intervals up to and including at discharge
3 Patient satisfaction questionnaire – at discharge and at 24 h
postcolonoscopy
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was administered through a mouthpiece connected to
an Entonox cylinder. This mouthpiece has a one-way
demand valve system, which is operated by the act of
inhalation of the patient and closes down when the
patient ceases to inhale. The Entonox group patients
then inhaled the gas initially until a MOAAS score of 4
was reached, and then colonoscopy was started. Patients
continued to inhale Entonox until the caecum was
reached, and subsequently as and when required while
the endoscope was being withdrawn. If the patient or
the colonoscopist found the procedure too uncomfort-
able, then they were able to administer additional
propofol intravenous sedation; this was given after a
washout of 5 min.
Monitoring
All patients were continually assessed throughout the
entire procedure, according to the guidelines of the
British Society of Gastroenterology [27] (see Table 1).
The aim of conscious sedation was that at all times the
patient should be able to obey commands, and hence an
MOAAS score of 4 was the target. The anaesthetist
marked the level of sedation every 3 min for both the
propofol and Entonox groups (Table 1). Postprocedure,
all patients were allowed to recover and be discharged
according to the existing protocols as mentioned in
Table 1.
An attending nurse was available throughout the
procedures. This individual had the responsibility of
assessing and recording medication administration, times
and time intervals related to the procedure, patient’s
physiological parameters and level of sedation.
Times and intervals recorded for all patients were as
follows: start of sedation, start of colonoscopy, time when
caecum was reached, withdrawal time, total colonoscopy
time, recovery time and time to discharge (time interval
between removal of the endoscope and when patient is
discharged).
Measurements
Primary outcomes
The primary end-point measured was the degree of pain
experienced by the patient during the procedure and
assessed on a validated 100-mm VAS. These measure-
ments were taken immediately, and at 15-min intervals
post procedure up to and including at discharge. Patients
also marked a VAS at 24 h post procedure to overcome
any persisting effects of sedation.
Secondary outcomes
The secondary end-points measured included satisfac-
tion of the patient, the nurse and the endoscopist (on a
100-mm VAS), manoeuvrability, depth of sedation, rate
of complications, time to reach caecum and total colo-
noscopy time, rate of completion, degree of psychomotor
recovery (using the previously validated letter cancellation
test) and time to discharge.
Patient satisfaction was measured using a modification
of a validated satisfaction questionnaire developed for
endoscopy [28]. Nurse and endoscopist satisfaction was
measured using a 100-mm VAS, as part of a separate
questionnaire.
Psychomotor recovery was assessed using a validated
psychometric test called the letter cancellation test [29].
This test measures concentration and perception. The
patient was presented with a sheet of paper containing a
printed paragraph of 20 rows of 40 randomly arranged
letters, and was then asked to read from left to right and
top to bottom, simultaneously marking through all the
occurrences of a predesignated letter. The number of
lines completed in 120 s and the number of occurrences
of the predesignated letter correctly identified were
recorded for scoring. The postprocedure scores were
then compared with their baseline scores to measure
recovery. The results are presented in terms of the
percentage recovery of psychomotor function (i.e. per-
centage recovery of the letter cancellation test score
compared with the preprocedure score). This test has
previously been shown to be an accurate, easy to
administer and efficient means of measuring psychomotor
recovery in the postendoscopy setting [29,30].
The endoscopists also marked a simple questionnaire
concerning degree of sedation, degree of ease of colo-
noscopy and difficulty in manoeuvring the patient. The
attending nurses also completed a questionnaire after the
procedure concerning the perceived adequacy of seda-
tion, ability of patients to assist with moving during the
procedure and maximal depth of sedation.
Demographic and clinical features recorded from all
patients included age, sex, weight, height, clinical indica-
tions, past and family history, results, procedural findings
and complications. Intraprocedural and immediate
postprocedure complications were noted by the anaes-
thetist. Patients were contacted at the end of 1 month
postprocedure to identify delayed complications.
Sedation complications were defined as a prolonged
drop in oxygen saturation below 90% for at least 30 s,
with the need for positive pressure ventilation using a
bag-valve system. Other complications recorded included
a prolonged drop in blood pressure below 90 mmHg,
heart rate below 60 or above 110 beats ⁄min.
Colonoscopic procedure
All colonoscopies were performed according to the
standard operating procedure with the use of Pentax
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video colonoscopes (Pentax, Hamburg, Germany).
Colonoscopy was carried out by JAG-certified, fully
independent colonoscopists. Completion to caecum was
documented using two out of the following three
landmarks: ileocaecal valve, appendiceal orifice or the
tri-radiate fold.
Statistical analysis and sample size calculation
This is an equivalence study. In this process, we start by
prespecifying delta (d), the absolute value of the differ-
ence that could be found between Entonox and prop-
ofol and still conclude that the two interventions are
equivalent. This is called the equivalence margin, and )d
to +d is the range within which the 95% confidence
interval (CI) of the difference in the mean between the
two groups can vary and still be of no clinical importance
[31]. The aim, therefore, is to check whether the CI for
the difference between the groups on various outcome
measures is within this range.
Estimates of sample size were based on the primary
outcome measure, which was the degree of pain
experienced by the patient and assessed using the
100-mm VAS. The variance was assumed to be around
30 points, as determined by previous studies [18] as
well as our own randomized controlled trial [32]. This
variance was assumed to be similar in both groups. The
two drugs would be considered equivalent if the 95%
two-sided confidence interval for the treatment differ-
ence, measured using the 100-mm VAS, falls wholly
within the interval ±15 mm. If the difference between
the propofol and Entonox groups is less than this
predetermined equivalence margin ()15 to +15 mm),
then the treatments would be considered equally effec-
tive or equivalent, even though one can never defini-
tively ‘prove’ equivalence.
With an alpha level of 0.05 (two-sided) and statistical
power of 80%, we used the sample size formula from
Jones et al. [31] for the two-sided case for comparison of
means in equivalence trials, indicating a requirement of
48 patients per group, or 96 patients total.
Differences in proportion were tested using the v2
test, resorting to Fisher’s exact test for smaller samples.
The primary outcomes (visual analogue scores), postop-
erative time to discharge and results of the letter
cancellation test were evaluated using the Mann–Whitney
U-test. Demographic and baseline characteristics were
compared with the use of a two-way analysis of variance
for continuous data and Fisher’s exact test for categorical
data. All analyses followed the intention-to-treat princi-
ple. All reported P-values are two-tailed. No interim
analyses were performed before the primary end-point
was analysed.
Results
Patients
During the study period, a total of 112 patients were
assessed for eligibility, of whom 100 patients participated
in the trial and 50 each were randomized to receive
Entonox or propofol (Fig. 1). Twelve patients were
excluded after eligibility assessment, as follows: eight
were ineligible (seven patients were postsurgical resec-
tion, one patient had severe chronic obstructive airways
disease) and four patients refused to participate. Among
those patients who refused to participate, two patients
said that they did not want to participate in any trial as
they were too anxious and the remainder said that they
had inhaled Entonox in the past and were not happy to
participate.
The baseline characteristics of patients were similar in
both groups, as shown in Table 3. More significantly,
there was no difference between the two groups in terms
of preprocedure anxiety scores (7.5 vs 8.4; P = 0.1).
There were no complications in either group.
Medication
Patients in the propofol group pressed the PCA handset
a median of four times [interquartile range (IQR) 1–7)]
during each procedure, with 96% of the attempts being
successful. The median dose of PCA propofol was 37 mg
and the median dose of TCI propofol was 137 mg. The
median total dose of propofol was 174.8 mg (range 148,
190). None of the propofol patients required additional
Fentanyl.
In the Entonox group, patients inhaled the gas until
the caecum was reached, and thereafter only 30%
Table 3 Baseline characteristics of patients in both groups.
Entonox Propofol
Gender (M:F) 29:21 24:26
Median age in years (range) 56.1 (42, 66) 60.4 (40, 71)
ASA class
1 08 (16%) 10 (20%)
2 33 (66%) 29 (58%)
3 09 (18%) 11 (26%)
Preprocedure anxiety (median) 7.5 8.4
Diagnosis
Colorectal cancer 6 4
Colorectal polyp 12 16
Diverticulitis 8 12
Colitis 7 3
Others ⁄ normal 21 16
Randomized controlled trial of sedation for colonoscopy S. Maslekar et al.
 2010 The Authors
52 Colorectal Disease  2010 The Association of Coloproctology of Great Britain and Ireland. 13, 48–57
(15 ⁄ 50) of the patients continued to need Entonox.
None of the Entonox patients required additional seda-
tion or conversion to the intravenous group.
Primary outcome: pain scores
The median pain score at discharge in the Entonox group
was 15.38 (IQR 14, 20), compared with 17.31 in the
Propofol group (IQR 10, 20). The 95% CI of the differ-
ence in means was )0.89, 5.02. This falls well within the
preset interval of )15, 15, implying that the two drugs
are equivalent in terms of pain relief. Likewise, no
statistically significant differences were found between
the two groups when assessed at 15 min or 24 h
postprocedure (Table 4).
Secondary outcomes
Depth of sedation
The median depth of sedation in the Entonox group was
4 (IQR 5–4), compared with the propofol group (median
3, IQR 5–3). These differences were not statistically
significant (P = 0.091), though the depth of sedation was
higher in the propofol group.
Manoeuvrability during the procedure
There was no difference in the manoeuvrability in
patients in both groups. The score was similar in both
groups (Entonox group, mean score 1, range 1–2 vs
propofol group, mean score 2, range 1–3), but the
differences did not reach statistical significance (P = 0.2).
The 95% CI of the difference in means between the two
groups ()1, 1) was well within the preset range (–2, 2).
Completion rates and procedure time
Total colonoscopy up to caecum or ileum was achieved in
all patients except two patients in the Entonox group and
onepatient in the propofol group (Table 5).Onepatient in
theEntonoxgrouphad an impassable stricture and another
had poor bowel preparation leading to incomplete colo-
noscopy. In the propofol group, the single incomplete
colonoscopy was because of an obstructing lesion in the
hepatic flexure. The two groups were similar in terms of
time to caecum and total procedure time (Table 5).
Table 4 Visual analogue scores (primary outcome measure).
Pain scores on VAS Entonox (IQR) Propofol (IQR) 95% CI
Predetermined
equivalence margin
At discharge 15.38 (14, 20) 17.31 (10, 20) )0.89, 5.02 )15, 15
15 min 15.78 (12, 20) 16.54 (10, 20) )0.93, 5.06 )15, 15
At 24-h post procedure 16.14 (14, 21) 17.89 (10, 20) )0.88, 5.03 )15, 15
CI, confidence interval; IQR, interquartile range; and VAS, visual analogue scale.
Table 5 Patient assessment.
Endoscopist assessment Entonox (IQR) Propofol (IQR)
Significance
(P-value) 95% CI
Predetermined
equivalence interval
Caecal intubation (%) 48 ⁄ 50 (96) 49 ⁄ 50 (98) 0.55 )0.56, )5, 5
Mean time to caecum (min) 13 (10, 16.25) 14 (12, 23.25) 0.18 )1.82, 3.82 )5, 5
Mean completion time (min) 22.6 (18, 28) 20.8 (17, 23) 0.09 )0.83, 4.36 )5, 5
Median difficulty of colonoscopy 24 22 0.79 – –
Satisfaction 96 (95, 98) 98 (96, 100) 0.26 )2.9, 0.26 )5, 5
Nurse’s assessment
Mian satisfaction score (out of 100) 95.8 (93.4, 98) 97.24 (95, 99) 0.34 )3.36, 0.49 )5, 5
Adequate sedo-analgesia 56 54 0.2 )5, 0.89 )5, 5
Manoeuvrability Score 1 2 0.2 – –
Patient assessment
Median satisfaction score 94 96 (94, 98) 0.10 )0.46, 3.6 )5, 5
Agree to repeat use of same sedation 46 48 0.56 – –
Remember start of procedure 39 ⁄ 50 42 ⁄ 50 0.39 – –
Remember end of procedure 41 ⁄ 50 45 ⁄ 50 0.35 – –
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Psychomotor recovery and time to discharge
The psychometric tests were administered immediately
upon the arrival of the patients in the recovery area and
then at 15-min intervals until the patients were dis-
charged. Inability of the patients to perform the tests
immediately on return to the recovery room was also
noted. All patients were discharged by the recovery room
nursing staff based on preexisting discharge criteria
(Table 1).
Patients in both groups demonstrated rapid recovery
of psychomotor function after the procedure (Table 6).
However, patients in the Entonox group had complete
recovery of psychomotor function at discharge com-
pared with the propofol group, where the median
recovery was 96% (IQR, 94,100; P = 0.04). It follows
that the time to discharge was also similar in both
groups (Table 6).
Patient, nurse and endoscopist satisfaction
Patients marked their satisfaction questionnaire at dis-
charge, but before they were given the results of the
colonoscopy to ensure that any bias was eliminated.
Patient satisfaction was similar in both Entonox and
propofol groups (Table 5). Also, a similar proportion of
patients agreed to repeat their procedure under same
sedation if required.
The attending nurses and endoscopists found no
differences in their assessment of satisfaction with either
Entonox or propofol sedation (Table 5).
Amnesia and additional sleep and return to normal
activities
At 24 h postprocedure, patients filled out a question-
naire regarding the number of additional hours of sleep
required and also the time taken to get back to routine
work. In the Entonox group, the resumption of normal
activities was at a median of 2–4 h, whereas in the
propofol group, the resumption was at a median of more
than 6 h (P = 0.02). As many as 54% of the patients in
the Entonox group reported requiring additional sleep
compared with 96% of patients in the propofol group
(P = 0.03).
Discussion
We have shown in this randomized controlled trial that
patient-controlled sedation for colonoscopy using either
our modified TCI-PCA infusion of propofol or Entonox
inhalation is equally effective (and safe). The modified
protocol for propofol provides adequate sedation and
analgesia, with equivalent patient satisfaction.
Propofol is a rapidly acting sedative drug with a short
duration of action and has attracted increasing attention
as it is well tolerated by patients and dramatically reduces
recovery time after successful sedation, in comparison
with routine intravenous sedation [33,34].
However, three primary concerns have been expressed,
and probably this has led to a relatively lesser uptake of
propofol for sedation during colonoscopy in the UK.
These relate to its narrow therapeutic range and the lack
of an antidote in cases of oversedation and ensuing
apnoea. The sedation provided by propofol is a contin-
uum, extending from mild sedation to general anaesthe-
sia. The third important concern is the difficulty in
manoeuvring patients during colonoscopy when sedated
with propofol.
To overcome these problems, we modified the tech-
nique of propofol administration to make it a patient-
maintained seation regime. The aim was to ensure that a
low dose of propofol was used while providing effective
pain relief, simultaneously maintaining the target level of
sedation (conscious sedation) and ensuring that the
patient was awake enough to move as required during
the procedure. In our study, patients in the propofol
group were initially given propofol to reach a target
(effect-site brain) concentration of 1.2 lg ⁄ kg ⁄ml. Once
this concentration was reached, patients were connected
to a PCA pump (containing propofol), and patients were
encouraged to press the PCA button if necessary
throughout the procedure, while a background infusion
of propofol was continued to maintain the preset target
concentration. Colonoscopy was started when the seda-
tion score reached 4 (on MOAAS), which is the
definition of conscious sedation. With this arrangement,
we have successfully sedated patients for colonoscopy,
Table 6 Recovery of psychomotor function and time to discharge.
Variables Entonox (IQR) Propofol (IQR) 95% CI
Significance
(P-value)
Recovery of function
Immediate 92% (89.5, 96) 90% (84, 92) )0.56, 4.56 0.79
15 min 99% (98.5, 100) 96% (91, 99) 1.1, 4.9 0.08
Discharge 100% 97% (94, 100) 0.06, 5.94 0.07
Time to discharge (mean) 27.86 min (22, 30.5) 28.08 min (23, 32) )2.28, 2.7 0.86
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achieving the target depth of sedation (conscious) and
allowing patients to be manoeuvred as necessary during
the procedure. The median depth of sedation in the
propofol group was 3, which was slightly higher than in
the Entonox group (median 4), but the difference did
not reach any statistical or clinical significance (in terms
of complications, difficulty in manoeuvring, recovery
from sedation, completion rates or time to completion).
We believe that this modified technique of propofol
sedation is very effective for colonoscopy. There were no
complications with the use of propofol; verbal commu-
nication was not lost in any of the patients, and
haemodynamic stability was maintained, even in the
elderly patients.
The primary outcome measure was the degree of pain
relief. We have shown that both propofol and Entonox
provide equivalent pain relief. The difference in means (of
VAS scores) between the two groups was within the preset
interval. We believe that good pain relief has a significant
bearing on patient satisfaction and other outcome mea-
sures. Moreover, propofol is basically a hypnotic with
minimal analgesic effect. In the absence of significant
analgesic effect, it is notable that none of the patients
needed additional analgesia and at the same time, theywere
highly satisfied with propofol. We believe that such an
effect is because of its amnesic and sedative properties. On
the other hand, we found that Entonox provides effective
sedation and analgesia for colonoscopy and is very safe. We
chose to compare propofol with Entonox because we have
previously demonstrated that the latter is more effective
than routine intravenous sedation, including opiates and
benzodiazepines [32]. Entonox was delivered through a
mouth piece with a one-way valve demand system, which is
activated by the patient’s inspired breath. Longer and
deeper breaths allowgreater volumes of gas tobe taken into
the lungs if necessary.We believe that this not only helps in
relieving discomfort ⁄ pain, but also alleviates patients’
anxiety, as they realize that a few deep breaths can relieve
pain, thus putting pain control in their hands as well. There
are no complications with the short-term use of Entonox;
however, continuous inhalation at analgesic doses for a
number of days has been associated with depression of the
bone marrow, megaloblastic anaemia and neurological
dysfunction.
However, the propofol delivery technique necessitated
the use of two pumps, the TCI pump and the PCA pump;
both were connected to the same intravenous line. Camp-
bell et al. [24] have previously modified the TCI system to
include PCA functionality. However, there were a number
of complications in their study, and the authors concluded
that the technique is feasible but needs further trials.
Moreover, this pump is not commercially available, and
the manufacturer was unable to modify the same because
of patent problems with their own pumps (personal
communication with manufacturer representative).
The onset of action was rapid in both groups, and the
effects could be seen within 1–2 min. In order to ensure
comparability between both groups, colonoscopy was
started when a MOAAS score of 4 was reached. The time
to caecum, total colonoscopy time and completion rates
were similar in both groups.
We found in our study that recovery of psychomotor
function was initially similar with both Entonox and
modified TCI propofol. However, at discharge, only
Entonox patients had complete recovery of psychomotor
function. As both the sedative regimes were associated
with early enhanced recovery and early discharge, there is
a potential for higher patient turnover and possibly
increased number of colonoscopies. It has been shown
that prolonged recovery from sedation is the major factor
that keeps the patient waiting in the recovery area after
the completion of colonoscopy. Vargo et al. [35] have
shown that if the recovery from sedation is faster than
achieved with conventional intravenous sedation, the
practice efficiency for colonoscopy can be improved, both
in terms of performing more procedures, as well as cost
effectiveness. We have shown that such improvement in
colonoscopy practice is achievable with both Entonox
and propofol because of reasons mentioned above.
Patient satisfaction is another area where current
practice is suboptimal. We have shown in our study that
patient satisfaction was high with both Entonox and
propofol. It is also important to note that more patients
in both groups agreed to use the same sedation for a
repeat procedure. Higher patient satisfaction has huge
implications; it is already known that uptake of screening
for colorectal cancer is still unsatisfactory. Any improve-
ment in patient experience with colonoscopy will help to
increase the number of patients willing to undergo the
procedure for screening. It is possible that high patient
satisfaction with both these agents could have been
related to the patients’ control of their own pain relief.
There are some limitations to our study. First, neither
patients nor endoscopists were blinded. We deliberately
chose not to blind because our aim was to establish the
safety and effectiveness of a new regime of propofol.
Moreover, it is difficult to blind patients and endoscopists
to Entonox as it makes a typical noise when inhaled,
though blinding has been achieved in previous studies.
Second, we started colonoscopy when the MOAAS score
of 4 was reached, rather than waiting for the target
concentration of propofol to be achieved. We adopted
this methodology to enable comparability in both groups
and also because the aim of all sedation in colonoscopy is
to provide conscious sedation. Third, this trial was
performed in a tertiary hospital; however, there is no
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reason to believe that the results cannot be extrapolated
to most hospitals and most endoscopists. Moreover, it
must be emphasized that the study was powered to detect
any differences in analgesic ability of the two drugs. In
other words, it was not powered to detect differences in
secondary measures. Finally, the propofol delivered was
controlled by the anaesthetist. This need for an additional
doctor to provide propofol seems nonfeasible given the
current budgetary constraints of most hospitals in UK as
well as all over the western world. However, several
studies have shown that nurses can be trained to provide
and monitor the administration of propofol for colonos-
copy. There is no reason why this technique cannot be
easily adopted by trained and qualified nurses to provide
sedation.
In summary, both our novel method of administering
propofol as well as Entonox inhalation provide effective
(and safe) sedation, and are associated with a high degree
of patient and endoscopist satisfaction. The depth of
sedation seems appropriate, allowing patients to be easily
manoeuvred during the procedures. We believe that
either Entonox or modified TCI-PCA propofol sedation
can be used to provide routine sedation for all patients
undergoing colonoscopy. However, there is a need for
further randomized controlled trials to compare different
methods of delivering propofol and a direct comparison
with different agents for sedation.
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